China biotech company GluBio raises $22m
China and US-based GluBio Therapeutics, which develops targeted protein degradation (TPD) drugs, has raised an extended Series A round of USD22m led by Qiming Venture Partners.
Lilly Asia Ventures and Kaitai Capital also took part. It brings total funding to nearly USD 90m since the company's inception in March 2021. Protein degraders tackle tough drug targets by taking over...
More on Greater China
Latest News
ADIA commits $83m to India's Aditya Birla Health Insurance
Abu Dhabi Investment Authority (ADIA) has agreed to invest INR 6.6bn (USD 83.5m) in India’s Aditya Birla Health Insurance (ADBHI) for a 10% stake.
Bain targets $102m Japan advertising take-private
Bain Capital has won board approval from Net Marketing, a Tokyo-listed online advertising and media management business, for a take-private that values the company at approximately JPY 13.6bn (USD 102m).
China's Insilico Medicine gets another $35m
Insilico Medicine, a China-based artificial intelligence-driven drug discovery company, has closed the second tranche of its Series D round on USD 35m, with Prosperity7 Ventures taking the lead.
Singapore crypto risk platform extends Series A to $24m
Singapore’s Merkle Science, a predictive crypto analytics platform, has raised USD 24m in Series A funding led by K3 Ventures, Darrow Holdings, and Beco Capital.